Neutralizing autoantibodies against GM-CSF are the cause of disease in ~90% of patients with PAP.1,14,17,18,23 We therefore tested the plasma of the patients for these antibodies and found that none had an abnormal increase in the level of GM-CSF autoantibodies (Figure S3H). This evidence concerns the gene CSF2 and pulmonary alveolar proteinosis.